Zai Lab Ltd (ZLAB) Stock Price & Analysis
Zai Lab Ltd (ZLAB) fell 2.34% to USD 19.22 as of July 25, 2026 at 03:05 UTC, according to Nexqual real-time market data.
ZLAB last closed at USD 19.68; the session ranged USD 18.92–19.52 on volume of 466,619 shares. Market capitalization is $2.17B, with a 52-week range of USD 15.96–41.2 (NGM). Source: Nexqual, July 25, 2026 at 03:05 UTC.
Key Statistics (as of July 25, 2026 at 03:05 UTC)
| Price | USD 19.22 |
|---|---|
| Change | ▼ 2.34% (down) |
| Previous Close | USD 19.68 |
| Open | USD 19.52 |
| Day Range | USD 18.92 – 19.52 |
| 52-Week Range | USD 15.96 – 41.2 |
| Volume | 466,619 shares |
| Market Cap | $2.17B |
| Exchange | NGM |
Technical Analysis (ZLAB)
Nexqual's technical model rates ZLAB "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 03:05 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.15 (neutral) |
| vs SMA50 | Above (USD 18.75) |
| MACD | 0.38 (positive) |
Analyst Ratings (ZLAB)
Wall Street analysts rate ZLAB "Strong Buy" based on 12 analysts, with a mean price target of USD 33.3 (range USD 21.6–52), per Nexqual as of July 25, 2026 at 03:05 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 33.3 |
| High Target | USD 52 |
| Low Target | USD 21.6 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (ZLAB)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.67 |
| Revenue Estimate | $103.95M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.46 vs est -0.53 ▲ beat |
| 2025-12-31 | USD -0.46 vs est -0.42 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.29 ▼ miss |
| 2025-06-30 | USD -0.37 vs est -0.42 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Financials & Fundamentals (ZLAB)
| Total Revenue | $453.28M |
|---|---|
| Revenue Growth (YoY) | -6.50% |
| Gross Margin | +8.11% |
| Operating Margin | -69.66% |
| Profit Margin | -39.29% |
| ROE | -24.19% |
| Debt / Equity | 35.03 |
| Current Ratio | 2.4 |
| Total Cash | $661.32M |
| Total Debt | $231.91M |
| Free Cash Flow | $-73.36M |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Financial Health Score (ZLAB)
Nexqual rates Zai Lab Ltd's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:05 UTC.
| Growth | Strong — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Critical — Gross margin 8%, operating -70% |
| Balance Sheet | Strong — $661M cash vs $232M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$73M, burning cash |
| Efficiency | Critical — ROE -24%, ROA -13.4% |
Ownership (ZLAB)
| Insider Ownership | +2.16% |
|---|---|
| Institutional Ownership | +31.25% |
| Shares Outstanding | 112.92M |
| Float | 91.71M |
| Short % of Float | +7.37% |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Leadership (ZLAB)
Zai Lab Ltd is led by Ying Du (age 59), Founder, Chairperson & CEO, per Nexqual as of July 25, 2026 at 03:05 UTC.
| Founder, Chairperson & CEO | Ying Du (age 59) |
|---|---|
| President and Head of Global Research & Development | Rafael G. Amado (age 61) |
| Chief Financial Officer | Yajing Chen (age 57) |
| Chief Operating Officer of Global R & D | James Yan DABT (age 61) |
Major Backers & Investors (ZLAB)
Notable institutional backers of Zai Lab Ltd include RTW Investments LP, RA Capital Management, L.P., Fidelity, according to Nexqual as of July 25, 2026 at 03:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 5.78% |
| RA Capital Management, L.P. | 5.02% |
| Fidelity | 1.91% |
| Frazier Life Sciences Management, L.P. | 1.67% |
| Citadel | 1.48% |
| BAMCO Inc. | 1.46% |
| Adar1 Capital Management, LLC | 1.25% |
| BARON SELECT FUNDS-Baron Emerging Markets Fund | 1.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.3% |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
From Zai Lab Ltd's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property Our commercial success depends, in part, on our ability to obtain and maintain proprietary protection for our know-how and innovation pertaining to our commercial products and product candidates as well as our core technologies; to operate without infringing, misappropriating, or otherwise violating the proprietary rights of others; and to prevent others from infringing, misappropriating, or otherwise violating our proprietary rights.
- We seek to protect our proprietary information, in part, by executing confidentiality agreements with our partners, collaborators, scientific advisors, employees, consultants, and other third parties.
- These confidentiality agreements are designed to protect our proprietary information and generally include clauses requiring assignment of inventions to us to grant us ownership of technologies that are developed through our relationship with the respective counterparty.
- Such agreements may not provide adequate protection of our proprietary information.
Partnerships
- In November 2024, we entered into a strategic collaboration with Pfizer that allows us to leverage the industry-leading commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to support sales of XACDURO in mainland China.
- NovoCure (Tumor Treating Fields) In September 2018, we entered into a license and collaboration agreement with NovoCure, pursuant to which we obtained an exclusive license under certain patents and know-how of NovoCure to develop and commercialize any Tumor Treating Fields (OPTUNE) products in all human therapeutic and preventative uses in the field of oncology in Greater China.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCM | HUTCHMED (China) Limited | USD 11.01 | ▼ 0.99% |
| LEGN | Legend Biotech Corporation | USD 22.22 | ▼ 5.57% |
| DNLI | Denali Therapeutics Inc. | USD 23.11 | ▼ 2.24% |
| GDS | GDS Holdings Limited | USD 31.63 | ▼ 3.27% |
| NBP | NovaBridge Biosciences | USD 1.77 | ▲ 1.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:05 UTC. This page is informational and not investment advice.